Trials / Completed
CompletedNCT01193140
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
Detailed description
An extension study to evaluate the safety of veliparib in combination with temozolomide in subjects with solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | veliparib | Dose orally twice daily for 7 days, consecutively, every cycle |
| DRUG | Temozolomide | Dose orally once daily for 5 days, consecutively, every cycle |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-09-01
- Last updated
- 2012-11-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01193140. Inclusion in this directory is not an endorsement.